In partnership with Bristol-Myers Squibb, Immuneering helped BMS understand why only a certain group of patients with melanoma were responding to YERVOY. We detected gene expression in a subset of immune cells and were able to show that patients with that gene had an increased survival benefit. This work resulted in a new patent application (WO2014078468).
Featured Publications
In published work together with Janssen, Immuneering helped identify why subgroups of multiple myeloma (MM) patients treated with DARZALEX had different response profiles through discovering differential expression of T-cell co-stimulation proteins in better responding patients. This work resulted in several published abstracts and presentations at the American Society of Hematology.
In partnership with Teva, Immuneering applied transcriptomics to characterize COPAXONE’s mechanism of action and compare it to potential generics, helping to ensure patient safety by providing new ways to more fully assess the biological impact of potential generics. This work resulted in several peer-reviewed publications.
Publications
Found 61 Results
Page 1 of 7
Page 1 of 7
Page 1 of 7
September 9, 2021
Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing
The lack of samples for generating standardized DNA datasets for setting up a sequencing pipeline or benchmarking the performance of different algorithms limits the implementation and uptake of cancer genomics….
Journal: Nature Biotechnology
Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing
Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing study…
Journal: Nature Biotechnology
April 30, 2021
Human transthyretin binding affinity of halogenated thiophenols and halogenated phenols: An in vitro and in silico study
Introduction: Daratumumab (DARA) is a human IgG1κ monoclonal antibody that binds with high affinity to a unique epitope on CD38. DARA monotherapy has shown promising activity in relapsed and/or refractory…
Journal: Chemosphere
April 27, 2021
A primer on applying AI synergistically with domain expertise to oncology
Abstract Background The concurrent growth of large-scale oncology data alongside the computational methods with which to analyze and model it has created a promising environment for revolutionizing cancer diagnosis, treatment,…
Journal: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
April 16, 2021
A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency
Oncopanel genomic testing, which identifies important somatic variants, is increasingly common in medical practice and especially in clinical trials. Currently, there is a paucity of reliable genomic reference samples having…
Journal: Genome Biology
Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions
Background Targeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing reference materials characterized by the U.S. Food and Drug Administration-led SEquence…
Journal: Genome Biology
April 12, 2021
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here we report the findings of…
Journal: Nature Biotechnology
October 14, 2020
Transparency and reproducibility in artificial intelligence
Breakthroughs in artificial intelligence (AI) hold enormous potential as it can automate complex tasks and go even beyond human performance. In their study, McKinney et al.1 showed the high potential…
Journal: Nature
October 12, 2020
Clinical landscape of oncolytic virus research in 2020
Oncolytic viruses (OVs) are a new class of cancer therapeutics. This review was undertaken to provide insight into the current landscape of OV clinical trials. A PubMed search identified 119…
Journal: Journal for ImmunoTherapy of Cancer
September 25, 2020
pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model
Huntington disease (HD), a devastating hereditary neurodegenerative disorder, is caused by an expansion of a CAG trinucleotide repeat that encodes a polyglutamine (polyQ) tract in the huntingtin (HTT) gene.
Journal: Cell Death & Disease
Page 1 of 7
